Aktis Oncology, Inc. insider trading

Every open-market purchase and sale by Aktis Oncology, Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.

Insider purchases, 5 years $114M 6 trades by 6 insiders 3 months later: median −20.3% (−19.2% vs S&P 500) Insider sales, 5 years $3.2M 5 trades by 3 insiders 3 months later: median −37.3% (−41.8% vs S&P 500)

Insider purchase Insider sale Marker size reflects trade value. Weekly closes adjusted for splits; may be delayed.

Aktis Oncology, Inc. insider open-market trades
Date	Insider	Trade	Shares	Price	Value	1M after	3M after	6M after

From insiders' Form 4 filings with the SEC: open-market purchases and sales only (awards, option exercises and shares withheld for tax are excluded), combined to one line per insider per day. "Plan" marks trades the filing says were made under a pre-set Rule 10b5-1 trading plan, which are scheduled in advance. Price changes run from the close on the trade date; hover a figure for the change relative to the S&P 500. Past moves don't predict future ones.

← Back to Aktis Oncology, Inc. · Funds · Politicians